AI Article Synopsis
- - The study investigated the use of liposomal resiquimod, an imidazoquinoline drug, for the systemic treatment of visceral leishmaniasis, a disease caused by Leishmania donovani that typically requires parenteral administration due to the drug's hydrophobic nature.
- - Researchers encapsulated resiquimod in liposomes using a specific technique and tested its effectiveness by injecting it into infected mice, finding that it significantly reduced parasite levels in key organs like the liver and spleen.
- - Results indicated that liposomal resiquimod boosted immune responses and was non-toxic, suggesting its potential as an effective treatment for visceral leishmaniasis and supporting further research for its clinical application.
Article Abstract
Objectives: The imidazoquinoline family of drugs are Toll-like receptor 7/8 agonists that have previously been used in the treatment of cutaneous leishmaniasis. Because of the hydrophobic nature of imidazoquinolines, they are traditionally not administered systemically for the treatment of visceral leishmaniasis. We formulated liposomal resiquimod, an imidazoquinoline, for the systemic treatment of visceral leishmaniasis.
Methods: By using lipid film hydration with extrusion, we encapsulated resiquimod in liposomes. These liposomes were then injected intravenously to treat BALB/c mice infected with Leishmania donovani.
Results: Treatment with liposomal resiquimod significantly decreased the parasite load in the liver, spleen and bone marrow. In addition, resiquimod treatment increased interferon-γ and interleukin-10 production in an antigen recall assay. Resiquimod was shown to be non-toxic in histology and in vitro culture experiments.
Conclusions: FDA-approved resiquimod, in a liposomal formulation, displays promising results in treating visceral leishmaniasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861330 | PMC |
| http://dx.doi.org/10.1093/jac/dkt320 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Remodeling tumor microenvironment using pH-sensitive biomimetic co-delivery of TRAIL/R848 liposomes against colorectal cancer.
Oncol Res
October 2024
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
Background: Despite significant advancements in the development of anticancer therapies over the past few decades, the clinical management of colorectal cancer remains a challenging task. This study aims to investigate the inhibitory effects of cancer-targeting liposomes against colorectal cancer.
Materials And Methods: Liposomes consisting of 3β-[N-(N', N'-dimethylamino ethane)carbamoyl]-cholesterol (DC-CHOL), cholesterol (CHOL), and dioleoylphosphatidylethanolamine (DOPE) at a molar ratio of 1:1:0.
Therapeutic liposomal combination to enhance chemotherapy response and immune activation of tumor microenvironment.
J Control Release
September 2024
Institution of Biology Leiden, Leiden University, the Netherlands. Electronic address:
Multiple oxaliplatin-resistance mechanisms have been proposed such as increase of anti-inflammatory M2 macrophages and lack of cytotoxic T-cells. Thereby oxaliplatin chemotherapy promotes an immunosuppressive tumor microenvironment and inhibits anti-tumor efficacy. It has been shown that toll-like receptor (TLR) agonists are capable of triggering broad inflammatory responses, which may potentially reduce oxaliplatin-resistance and improve the efficacy of chemotherapy.
View Article and Find Full Text PDFResiquimod-loaded cationic liposomes cure mice with peritoneal carcinomatosis and induce specific anti-tumor immunity.
J Control Release
August 2024
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada. Electronic address:
Article Synopsis
- Peritoneal carcinomatosis (PC) has a high recurrence and mortality rate after treatments due to incomplete cancer removal, prompting the development of new therapies.
- Two cationic liposomal formulations were created to deliver the immune-activating agent resiquimod (R848) directly to the peritoneum, significantly increasing its retention and enhancing immune responses without raising levels in the bloodstream.
- In mouse models of colon cancer, these formulations combined with oxaliplatin improved the infiltration of immune cells and achieved a 60-70% cure rate, demonstrating strong antitumor immunity and long-term immune memory against the specific cancer type.
Exploring in vivo combinatorial chemo-immunotherapy: Addressing p97 suppression and immune reinvigoration in pancreatic cancer with tumor microenvironment-responsive nanoformulation.
Biomed Pharmacother
June 2024
Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
Pancreatic ductal adenocarcinoma (PDAC) has an extremely devastating nature with poor prognosis and increasing incidence, making it a formidable challenge in the global fight against cancer-related mortality. In this innovative preclinical investigation, the VCP/p97 inhibitor CB-5083 (CB), miR-142, a PD-L1 inhibitor, and immunoadjuvant resiquimod (R848; R) were synergistically encapsulated in solid lipid nanoparticles (SLNs). These SLNs demonstrated features of peptides targeting PD-L1, EGFR, and the endoplasmic reticulum, enclosed in a pH-responsive polyglutamic (PGA)-polyethylene glycol (PEG) shell.
View Article and Find Full Text PDFSupramolecular Lipid Nanoparticles Based on Host-Guest Recognition: A New Generation Delivery System of mRNA Vaccines For Cancer Immunotherapy.
Adv Mater
June 2024
Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, 100084, P. R. China.
Dendritic cell (DC) maturation is a crucial process for antigen presentation and the initiation of T cell-mediated immune responses. Toll-like receptors play pivotal roles in stimulating DC maturation and promoting antigen presentation. Here, a novel message RNA (mRNA) cancer vaccine is reported that boosts antitumor efficacy by codelivering an mRNA encoding tumor antigen and a TLR7/8 agonist (R848) to DC using supramolecular lipid nanoparticles (SMLNP) as a delivery platform, in which a new ionizable lipid (N2-3L) remarkably enhances the translation efficiency of mRNA and a β-cyclodextrin (β-CD)-modified ionizable lipid (Lip-CD) encapsulates R848.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!